RNA, U2 small nuclear 46, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU2-46P profile across patient tissues and cancer cell-line models. RNU2-46P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, RNU2-46P is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, RNU2-46P RNA expression shows 12,224 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, STAD, and THYM as cancer lineages where RNU2-46P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU2-46P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU2-46P survival associations across molecular data types. RNU2-46P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU2-46P RNA expression–survival associations across cancer types. High RNU2-46P expression shows unfavorable associations in COAD, READ, LUSC, LIHC and TGCT, but favorable associations in GBM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify COAD as the clearest survival context for RNU2-46P RNA expression.
This table summarizes RNU2-46P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU2-46P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU2-46P shows lower tumor expression in THCA and KICH and higher tumor expression in STAD. The STAD box plot shows higher RNU2-46P RNA expression in tumor versus normal tissue (log2 FC = +0.348, t-test p = .004).
This table shows molecular features associated with RNU2-46P in patient tissues and cancer cell lines. In patient samples, RNU2-46P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
